The case and the decision

The teaching case combines Crohn-like inflammation, superficial infections, normal PMA-stimulated DHR screens, impaired killing after bacterial uptake and markedly reduced oxidase activity in an EBV-transformed B-cell line. The team is considering whether the normal screen excludes an oxidase defect and whether a classic CGD prognosis automatically applies.

The physiological explanation

A PMA-DHR assay asks how the cell responds to one soluble laboratory stimulus. It does not measure every step of oxidase activity around an ingested particle. In a 24-patient p40phox study, particle-triggered neutrophil activity and B-cell oxidase activity were impaired while PMA-DHR was normal or only mildly impaired. [1]

That is why the apparent contradiction is informative: the test conditions differ. Appropriate particle-based functional testing and NCF4 analysis address the remaining hypothesis more directly.

How the retained answers differ

Both tools explain the mismatch and reach the same leading hypothesis. MontMedical explicitly keeps genetic confirmation pending and separates assessment, assay limitations and research evidence. OpenEvidence more directly rejects the two meeting positions and connects the discussion to the proposed infliximab decision.

Its shorthand that PMA drives assembly independently of p40phox is stronger than needed. The useful, supported observation is stimulus- and cell-dependent impairment; the normal result is not a universal bypass rule.

What a fair comparison preserves

OpenEvidence's clear response to the actual treatment question is a strength. Conversely, a milder phenotype in one p40phox cohort cannot establish zero future infection risk for an unconfirmed individual. The retained pair illustrates the value of precise assay interpretation and a distinct immediate-decision section, rather than establishing a diagnostic victory for either tool.

For a slower explanation of the mechanism, read the annotated screening-test case.